NEW
Stock Screener with Intrinsic Value
Novo Nordisk A/S (NVO)
Last Price$86.30.8%
Market Cap$384.7B
LTM Free Cash Flow
DKK 10.1B
Reverse DCF (Implied FCF growth)
11.2%
3Y Free Cash Flow CAGR
18.8%
LTM Revenue
DKK 40.4B
Reverse DCF (Implied Revenue growth)
11.8%
at normalized FCF margin 23.7%
3Y Revenue CAGR
26.2%
NVO Reverse DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
NVO Free Cash Flow
Crunching data... Almost there!
NVO Growth
Crunching data... Almost there!
NVO vs Peer Set: Reverse DCF comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for NVO
DCF value calculator
Peter Lynch Fair Value
Discount rate
Relative Value
Earnings growth model
Peter Lynch charts
Margin of safety
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Novo Nordisk A/S Reverse DCF (discounted cash flow) valuation?
As of Sep 30, 2024, Novo Nordisk A/S's Reverse Discounted Cash Flow (DCF) valuation estimates its Free Cash Flow growth at 11.2%.
What is Novo Nordisk A/S WACC?
As of Sep 30, 2024, Novo Nordisk A/S's Weighted Average Cost of Capital (WACC) is approximately 6.9%.
What is Novo Nordisk A/S Free Cash Flow?
As of Sep 30, 2024, Novo Nordisk A/S's Free Cash Flow is DKK 10.1B.